ClinicalTrials.gg
RecruitingNCT05604560Updated Oct 7, 2026

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

A Phase 2 interventional study of Tislelizumab and SX-682 in Pancreatic Cancer, sponsored by Lei Zheng. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Lei Zheng · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
957th of 1,573
25 · median 37
Started
2023
with 76 others
Phase 2
488 of 1,850
45 open now
Primary completion
2027-12
later than 275 of 468 live
Registered
1,556th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 957th largest by planned enrollment of the 1,573 interventional ones that give a count, is one of 77 that started in 2023, is one of 488 in phase 2, reaches primary completion later than 275 of the 468 other live ones, and was the 1,556th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Pancreatic cancer
  • Adenocarcinoma
  • Resectable pancreas cancer
  • Tislelizumab
  • Anti-PD-1
  • PD-L1
  • Antibody
  • SX-682
  • CXCR1/2 (chemokine receptor)
  • CXCR1/2 inhibitor
  • Small molecule
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign a written document.
  • Age ≥18 years.
  • Newly diagnosed have or cytologically proven adenocarcinoma of the pancreas.
  • Tumor must be resectable.
  • Patient's acceptance to have a tumor .
  • performance status 0 or 1
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  • For both Women and Men, must use acceptable form of while on study.

Exclusion criteria

Exclusion Criteria:

  • Have received any anti-pancreatic cancer therapy.
  • Have been diagnosed with another whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study.
  • Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures
  • Subjects with active, known or suspected disease that may relapse.
  • Systemic therapy (> 10mg daily prednisone equivalent) or therapy within 14 days of first dose of study drug administration.
  • Active infection requiring systemic therapy.
  • Infection with or or C at screening•
  • History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.
  • Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Prior stem cell transplantation or organ transplantation
  • Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.
  • Have received a ≤ 28 days before first dose of study drug.
  • Use of prolonging drugs within 2 weeks before the start of SX-682 dosing and for the length of the study.
  • demonstrating a QTc interval ≥ 470 msec or patients with congenital long QT syndrome.
  • Severe reaction to any monoclonal antibody.
  • Concurrent participation in another therapeutic clinical study
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Arm A - Tislelizumab and SX-682

    Drug: Tislelizumab · Drug: SX-682

Interventions

  • Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.

    Also known as: BGB-A317

  • DrugSX-682

    Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.

06

What researchers measure

Primary outcomes

  1. Change in Immune response rate as assessed by density of intratumoral granzyme B+ CD137+ T cells

    The change in density of intratumoral granzyme B+ CD137+ T cells before and after neoadjuvant treatment with tislelizumab and SX-682.

    Time frame: Baseline and 2 weeks

  2. Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response

    The number of patients with a grade 0-2 pathologic response as defined by the College of American Pathologists (CAP) tumor regression grading system.

    Time frame: 4 years

Secondary outcomes

  1. Number of participants experiencing grade 3 or above drug-related toxicities

    When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.

    Time frame: 4 years

  2. Overall Survival (OS)

    OS is defined as the time from the first dose of study treatment to death from any cause. Patients who have not died will be censored at the last date known to be alive. Estimation based on the Kaplan-Meier curve.

    Time frame: 4 years

  3. Disease Free Survival (DFS)

    DFS is defined as the time from the first dose of study treatment until evidence of disease recurrence or death from any cause. For patients who have not progressed, relapsed, or died at the time of analysis, DFS will be censored on the date of last visit where disease progression was evaluable. Estimation based on the Kaplan-Meier curve.

    Time frame: 4 years

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.

Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 49 months is below that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2022
First posted
Nov 3, 2022
StartActual
Nov 8, 2023
Primary completionEst.
Dec 2027was Sep 2026
CompletionEst.
Dec 2028was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 7, 2026
Sites
2 sites changed recruiting status (1 now completed, 1 now recruiting)
Show 2 sites
  • Johns Hopkins SKCCC · Baltimore, United Statesno status→Completed
  • The University of Texas Health Science Center San Antonio · San Antonio, United Statesno status→Recruiting
Oct 7, 2026
Primary completion
Sep 2026→Dec 2027
Oct 7, 2026
Study completion
Sep 2026→Dec 2028
Oct 7, 2026
Contact
Study contact now listed: added g•••@uthscsa.edu · •••5798; added z•••@uthscsa.edu. See the current contact
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The University of Texas Health Science Center San Antonio · San Antonio, United StatesContact added g•••@uthscsa.edu · •••5798Contact added (no phone or email listed)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Recruiting
    2 sites changed recruiting status (1 now completed, 1 now recruiting)
    Show 2 sites
    • Johns Hopkins SKCCC · Baltimore, United Statesno status→Completed
    • The University of Texas Health Science Center San Antonio · San Antonio, United Statesno status→Recruiting
    Primary completion Sep 2026→Dec 2027
    Study completion Sep 2026→Dec 2028
    Contact Study contact now listed: added g•••@uthscsa.edu · •••5798; added z•••@uthscsa.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The University of Texas Health Science Center San Antonio · San Antonio, United StatesContact added g•••@uthscsa.edu · •••5798Contact added (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05604560
Lead sponsor
Lei Zheng
Collaborators
BeiGene, Syntrix Biosystems, Inc.
Responsible party
Lei Zheng (Executive Director of University of Texas Health Science Center at San Antonio Cancer Center, The University of Texas Health Science Center at San Antonio) — Sponsor-investigator
First posted
Nov 3, 2022
Start date
Nov 8, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Epp Goodwin
Contact
goodwine@uthscsa.edu
210-450-5798
Lei Zheng, MD
Contact
zhengl@uthscsa.edu
Lei Zheng, MD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SX-682

Start the discussion